Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions
about
Updates in Therapy for Advanced MelanomaTrametinib: a MEK inhibitor for management of metastatic melanomaTen things you should know about protein kinases: IUPHAR Review 14RAF inhibitors that evade paradoxical MAPK pathway activationChemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E ConformationComparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical useSelective Targeting of CTNBB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing DrugsParadoxical activation of MEK/ERK signaling induced by B-Raf inhibition enhances DR5 expression and DR5 activation-induced apoptosis in Ras-mutant cancer cellsManaging leptomeningeal melanoma metastases in the era of immune and targeted therapy.Selective anti-cancer agents as anti-aging drugsTargeting drivers of melanoma with synthetic small molecules and phytochemicals.Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma modelIn vitro long-term treatment with MAPK inhibitors induces melanoma cells with resistance plasticity to inhibitors while retaining sensitivity to CD8 T cells.Emerging BRAF inhibitors for melanoma.New RAF kinase inhibitors in cancer therapy.Towards combinatorial targeted therapy in melanoma: from pre-clinical evidence to clinical application (review).Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation.Vemurafenib for the treatment of BRAF mutant metastatic melanoma.Future of combination therapy with dabrafenib and trametinib in metastatic melanoma.MEK Inhibitors in the Treatment of Metastatic Melanoma and Solid Tumors.Patient-derived tumor xenograft models for melanoma drug discovery.Novel melanoma therapy.Clinical development landscape in GIST: from novel agents that target accessory pathways to revisiting non-targeted therapies.Potential therapeutic targets of epithelial-mesenchymal transition in melanoma.Dabrafenib for the treatment of melanoma.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.Impairment of cocaine-mediated behaviours in mice by clinically relevant Ras-ERK inhibitors.Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic MelanomaDabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition.The safety and efficacy of dabrafenib and trametinib for the treatment of melanoma.Development of encorafenib for BRAF-mutated advanced melanoma.Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma.Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF (V600) mutation-positive solid tumors: a phase 1 study.
P2860
Q26771119-3EC83B87-E65F-409C-8EFC-A09C83AAFE04Q26782976-B7CBB4C6-4041-4744-96F6-C876A7AC068FQ26849417-FDB9EA0F-A9DC-4CD4-ADB3-1148C1FA8EB1Q27702299-00FDE38D-BADF-425D-BA8E-963B9454E9F9Q27727954-23CBAD08-7357-41C8-B12B-067520CF0A92Q28541231-CE1F2098-B329-4155-891B-668DF95522ABQ28547522-70295E7F-7A92-4DB5-9119-FE03D3E26AB4Q28833514-5C030642-AFFC-46D5-8EA3-A5F7DFE97566Q30251581-0F5DCEC5-6100-4D0C-875A-018E02B3A7EBQ34392470-1AFCFF0A-3AC9-4CCF-B9CC-982FC771186DQ36141097-BDC65EF3-EEA0-46D3-B6DF-E80868D8BFE9Q36998897-293AE1A5-9B8D-4124-A1D9-7A20DF460B78Q37220424-C03CDBFA-7605-4D8F-B740-C17E935B964EQ37689031-6ADC9F5F-3090-46F9-A094-FD82E9B88FC3Q37720016-BDE35771-5877-45B7-A082-C0D532C77DACQ38145387-5B6770E1-F3EE-428C-BDE1-8247F6ED5267Q38207082-3EBF07EF-56D2-405A-A495-EE00729DA4B6Q38219616-0970624B-8514-4637-8103-3EE79A24A30BQ38228386-5F5D427F-0482-457B-A1EE-9736BD865927Q38357122-6859BD67-EE15-4961-A5A5-EAA3703679DBQ38578960-C03C0136-0321-4A15-BEA4-3C593165A3ABQ38679954-A7253CD7-18CD-4501-A1B0-F622A245F811Q38907413-02E0C6E9-13D0-4B19-9F66-6F08C84932B2Q38923489-931271CD-2482-4AE4-965C-36B8F69EA233Q38925022-78643000-4826-4B08-A4EB-EDFDABF88ACAQ39107981-95EC42D5-A5E8-4602-A248-F197F9BD2A23Q39212238-4453AEB3-BFA3-4B5B-92D0-62A7F3797E48Q39294398-B258BA3E-B242-4865-9C54-8E2F2FF3FE57Q39329582-DFED0CA1-03C4-43A4-840C-9A1C346E8A13Q39648474-3C590BEB-D22A-44D2-B690-210829F94206Q41249331-8B911714-E29A-4B68-BD00-E33324CCC7C1Q42262009-DA1F8408-0467-4C3B-BF3A-22867EB9877BQ47096483-1AFBDB42-D76F-4A7A-9444-0A112F0A76F6Q47549324-12D7A2EC-E8D9-4479-9429-4021E7286CA7Q47550452-17DFAFD5-249D-4FAC-A291-C05977E1218AQ48108178-02AF762B-DEB9-493D-8F64-A58F37F483C5Q48263612-04748547-1A7A-47DC-B6E4-9BCF838DE270Q49021003-BA3E57E8-AD15-4348-9B36-60BE357C7A6BQ50068807-22CCBEE6-01EE-4563-9BFC-5423256D5D04Q50209952-5004A94F-A920-44FA-9467-36F8A758F6B6
P2860
Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions
description
2013 nî lūn-bûn
@nan
2013 թուականին հրատարակուած գիտական յօդուած
@hyw
2013 թվականին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@ast
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en-gb
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@nl
type
label
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@ast
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en-gb
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@nl
prefLabel
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@ast
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en-gb
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@nl
P2093
P2860
P3181
P1433
P1476
Dabrafenib; preclinical charac ...... mbination reduced skin lesions
@en
P2093
Alastair J King
Angela Hughes-Earle
David E Uehling
Hongwei Qi
Jingsong Yang
Joseph A Erhardt
Katherine G Moss
Kelly E Fedorowicz
Kimberly N Smitheman
Laurie S Kane-Carson
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0067583
P407
P577
2013-01-01T00:00:00Z